2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2708

Type 17 Immunity in Spondyloarthritis Is Expanded Across Multiple Lymphocyte Subsets
Abstract Number: 2068

Type 2 Innate Lymphoid Cells – Cellular Source of Profibrotic Mediators Rapidly and Persistently Recruited in Experimental Fibrosis and Systemic Sclerosis
Abstract Number: 1669

Type 3 Innate Lymphoid Cells Numbers in Peripheral Blood Predict Ustekinumab (Stelara) Therapy Responsiveness in Psoriatic Disease Cases with Subclinical Imaging Enthesopathy
Abstract Number: 1340

Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution
Abstract Number: 1827

Type I IFN Signature Low and High SLE Subjects with Moderate to Severe Disease Activity Have Distinct Gene Expression Signatures of Immunologic Pathways and Cell Types
Abstract Number: 1082

Type I/II Interferon Commits to Abnormal Expression of Chemokine Receptor on B Cells in Patients with Systemic Lupus Erythematosus
Abstract Number: 479

Type II Collagen Secreted from Articular Chondrocytes Is Mainly Destroyed By Cathepsin S in RA Mice
Abstract Number: 2938

U4ATAC Mutation Is Associated with an Immune Dysregulation Syndrome Characterized By Primary Immunodeficiency, Short Stature and Polyglandular Endocrinopathy
Abstract Number: 1265

Ultra-High Field MRI and Biomechanical Investigation of Vertebral Bone Microarchitecture
Abstract Number: 147

Ultrasonographic Evaluation of Subclinical Enthesitis in Patients with Psoriasis
Abstract Number: 960

Ultrasonographic Improvement of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated with Ustekinumab for Chronic Plaque Psoriasis: A 52-Week, Prospective, Open Label, Controlled Cohort Study
Abstract Number: 150

Ultrasonography and Magnetic Resonance Imaging Changes in Polymyalgia Rheumatica Patients Treated By Tocilizumab
Abstract Number: 1003

Ultrasonography Changes during the Course of Septic Arthritis ARE Associated with Functional Outcome
Abstract Number: 1401

Ultrasonography of Major Salivary Glands in Juvenile SjöGren’s Syndrome − Preliminary Findings in a Multi-Center Study
Abstract Number: 3029

Ultrasonography of Major Salivary Glands in Patients Suspected with Primary Sjögren’s Syndrome: Comparison with Salivary Gland Biopsy and Classification Criteria

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].